New cocktail of drugs shows promise for tough bile duct cancer
NCT ID NCT05742750
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a combination of three drugs—camrelizumab, apatinib, and chemotherapy (gemcitabine plus cisplatin)—in 49 people with advanced biliary tract cancer that could not be removed by surgery. The goal was to see if the combo is safe and how well it shrinks tumors. Results could point to a new first-line treatment option.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
camrelizumab, apatinib, gemcitabine, cisplatin
What this could lead to
If successful, this combination could offer a new first-line treatment option for people with advanced biliary tract cancer, potentially improving tumor shrinkage and disease control.
What could go wrong
This is an early-phase, single-center trial with only 49 participants, so results may not apply broadly. The combination also carries risks of serious side effects from chemotherapy and immunotherapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BILIARY TRACT CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cancer center of SunYat-sen University
Guangzhou, Guangdong, 510060, China